AbbVie is set to acquire Aliada Therapeutics for $1.4 billion, gaining access to Aliada's blood-brain barrier crossing technology and Alzheimer's candidate, ALIA-1758.
AbbVie is set to acquire Aliada Therapeutics for $1.4 billion, gaining access to novel blood-brain barrier (BBB) crossing technology for CNS therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.